In the midst of the COVID-19 pandemic, we have new appreciation for the role of public health. While our hospitals and other health facilities are turned toward preparing for the worst part of the outbreak in the U.S., we also know that those of you battling C. diff infections still …
Last month our executive director and two members of our Advocates Council, Christina Fuhrman and Eric Petrosinelli, joined the Pew Charitable Trusts “Stand Up to Superbugs” fly-in. They joined 37 other Americans from all across the country to meet with the representatives to share their superbug stories and expertise and …
Fecal microbiota transplant (FMT) as a treatment for C. difficile infections has skyrocketed over the past decade. While it has saved tens of thousands of lives, FMT remains controversial and the Food and Drug Administration (FDA) has been slow to formalize its regulatory status. This has left doctors, scientists, drug …
The Food and Drug Administration (FDA) issued a Safety Alert today Regarding Use of Fecal Microbiota for Transplantation and Additional Safety Protections Pertaining to COVID-19. According to the alert, “FDA is informing health care providers and patients of the potential risk of transmission of SARS-CoV-2 virus by the use of fecal …
In recognition of C. diff Awareness Month, this past November Peggy Lillis Foundation (PLF) launched our new public education campaign, “See C. diff.” The campaign was based from Cdiff.org and included a range of educational media. We are delighted to report that the campaign did incredibly well reaching hundreds of …
